Efficacies of Various Surgical Regimens in the Treatment of Renal Calculi Patients: a Network Meta-Analysis in 25 Enrolled Controlled Clinical Trials

Wang, Yan‐Bo; Cui, Yanxin; Song, Junnian; Yang, Qian; Wang, Gang

doi:10.1159/000492246

Cited by 7 publications

(5 citation statements)

References 41 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The node splitting method was used to determine the consistency between direct or indirect evidence (Zhang and Xiao, 2018 ). Based on the results, to choose a consistent or inconsistent model, a consistency model was selected for further analysis when the results of node-splitting are P 0.05 (Wang et al, 2018 ). To help interpret ORs or WMDs, the surface under the cumulative ranking curves (SUCRA) (Salanti et al, 2011 ; Mbuagbaw et al, 2017 ) was used to calculate each intervention’s probability.…”

Section: Network Meta-analysismentioning

confidence: 99%

Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis

et al. 2021

Drug Delivery

View full text Add to dashboard Cite

Background: Pulmonary arterial hypertension (PAH) is a severe and fatal clinical syndrome characterized by high blood pressure and vascular remodeling in the pulmonary arterioles, which is also a rapidly progressing disease of the lung vasculature with a poor prognosis. Although PAH medication made great advances in recent years, the efficacy and safety of the medication are unsatisfactory. Therefore, we aimed to update and expand previous studies to explore the efficacy and safety of PAH-targeted medications. Methods: Relevant articles were searched and selected from published or publicly available data in PubMed, Cochrane Library, CNKI, PsycInfo, and MEDLINE (from inception until October 1 st , 2020). To assess the efficacy and safety of PAH therapies, five efficacy outcomes [6-minute walking distance (6MWD), mean pulmonary arterial pressure (mPAP), WHO functional class (WHO FC) improvement, clinical worsening, death] and two safety outcomes [adverse events (AEs), serious adverse events (SAEs)] were selected. And 6MWD was regarded as the primary efficacy outcome. Results: 50 trials included with 10 996participants were selected. In terms of efficacy, all targeted drugs were more effective than placebo. For 6MWD, Bosentan + Sildenafil, Sildenafil, Bosentan + Iloprost were better than others. Bosentan + Iloprost and Bosentan + Sildenafil were better for mPAP. Bosentan + Iloprost and Ambrisentan + Tadalafil were more effective in improving WHO FC. Bosentan + Tadalafil and Bosentan + Iloprost had the Ambrisentan probability to reduce the incidence of clinical worsening. It is demonstrated that Ambrisentan had clear benefits in reducing all-cause mortality. In terms of safety, no therapies had been shown to reduce the incidence of SAEs significantly, and Ambrisentan + Tadalafil significantly increased the incidence of AEs. Conclusions: Phosphodiesterase 5 inhibitor (PDE5i) + Endothelin Receptor Antagonists (ERA) seems to be better therapy for PAH. Prostacyclin analogs (ProsA) + ERA appear promising, though additional data is warranted. Registration PROSPERO CRD42020218818.

show abstract

Section: Network Meta-analysismentioning

confidence: 99%

Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis

et al. 2021

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…There is a growing body of literature that recognizes the importance of minimally invasive methods such as retrograde intrarenal surgery (RIRS) in the management of renal stone disease [ 1 ]. RIRS provides endoscopic treatment of renal stones with the help of fiber-optic, laser, and radiation technologies, without any incision.…”

Section: Introductionmentioning

confidence: 99%

Multi-aspect analysis of ureteral access sheath usage in retrograde intrarenal surgery: A RIRSearch group study

Özman

Akgül

Başataç

et al. 2024

Asian Journal of Urology

View full text Add to dashboard Cite

“…Given the improvements in technology and development of new devices, open surgery has become obsolete and minimally invasive approaches including extracorporeal shockwave lithotripsy (ESWL), ureterorenoscopy (URS) and percutaneous nephrolithotomy (PCNL) are standard treatments for urinary stone disease. Obtaining a stone-free status is one of the main parameters of surgical success and outcomes besides complications, hospital stay and renal function [2]. Although the stone-free rate is often used to compare effectiveness of different treatment modalities, there is no consensus on what constitutes a successful procedure or a stone-free status and, on the type and timing of imaging modality used to assess this status.…”

Section: Introductionmentioning

confidence: 99%

“…America (median/[IQR] = 3 mm/[2][3][4], p = 0.015). Similarly, European urologists considered a smaller threshold for CIRF compared to Asian urologists (median/[IQR] = 2 mm/[2-3] vs 3 mm/[2][3][4], p = 0.001).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Definition of clinically insignificant residual fragments after percutaneous nephrolithotomy among urologists: a world-wide survey by EAU-YAU Endourology and Urolithiasis Working Group

Tonyalı

Emiliani

Şener

et al. 2022

Cent european J Urol

View full text Add to dashboard Cite

INTRODUCTION The aim of this article was to evaluate the current perception of urologists as to what size is considered as a clinically insignificant residual fragment (CIRF). MATERIAL AND METHODS A survey was globally distributed to the members of the Endourological Society via SurveyMonkey. RESULTS A total of 385 participants responded to the survey on CIRF. Most participants considered 2 mm (29%) as CIRF threshold, followed by 3 mm (24%), 4 mm (22%), 0 mm (14%), 5 mm (8%) and 1 mm (3%). North American urologists considered CIRF to be smaller than urologists from Asia, Eurasia and South America, (p-values ≤0.001, 0.037 and 0.015 respectively). European urologists identified smaller CIRF in comparison to Asian urologists (p-value = 0.001). Urologists mainly using a pneumatic lithotripter accepted larger fragments as CIRF, compared to urologists mainly using ultrasonic devices or a combination of ultrasonic and pneumatic devices (p-value = 0.026 and 0.005 respectively). Similarly, urologists mainly performing X-Ray and ultrasound as post-operative imaging accepted larger fragments as CIRF in comparison to urologists mainly performing non-contrast computed tomography (p-value = 0.001). CONCLUSIONS What is considered as CIRF varies between urologist from different continents and seems to be associated with the lithotripter used and the post-operative imaging modality of preference to assess treatment success.

show abstract

Efficacies of Various Surgical Regimens in the Treatment of Renal Calculi Patients: a Network Meta-Analysis in 25 Enrolled Controlled Clinical Trials

Cited by 7 publications

References 41 publications

Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis

Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis

Multi-aspect analysis of ureteral access sheath usage in retrograde intrarenal surgery: A RIRSearch group study

Definition of clinically insignificant residual fragments after percutaneous nephrolithotomy among urologists: a world-wide survey by EAU-YAU Endourology and Urolithiasis Working Group

Contact Info

Product

Resources

About